VIRAMUNE 50 mg/5 ml, suspension buvable

( ARTG ) Viramune (nevirapine) oral suspension in combination with antiretroviral agents is indicated for the treatment of HIV-1 infection in adults and children over the age of 2 months.​​​‍​​‍​​​​‍​​‍‍ Viramune XR (nevirapine) extended-release tablets in combination with antiretroviral agents is indicated for the treatment of HIV-1 infection in adults and children over the age of three years. Extended-release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used. Resistant virus emerges rapidly when Viramune is administered as monotherapy or in dual combination therapy with an antiretroviral agent. Therefore, Viramune should always be administered in combination with at least two additional antiretroviral agents.